Foreword
May 2026
Authored by ANZSBT Clinical Transfusion Practice Committee, The Australian and New Zealand Society of Blood Transfusion (ANZSBT) Council is pleased to release this Position Statement on Prevention of Transfusion-Transmitted Cytomegalovirus (TT-CMV).
Scope
Summary
The collective evidence supports the use of pre-storage leucodepleted blood components as “CMV-safe” for immunosuppressed patients.
CMV-seronegative cellular blood components do not offer additional benefit over leucodepletion in any population including immunosuppressed patients.
Download
ANZSBT Position statement on prevention of TT-CMV May26 FINAL
Size: 366 KB
Download